Find Vadadustat manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

GLOBAL SALES INFORMATION

US Medicaid

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1000025-07-9, Akb-6548, Pg-1016548, Vadadustat [usan], N-(5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl)glycine, B506
Molecular Formula
C14H11ClN2O4
Molecular Weight
306.70  g/mol
InChI Key
JGRXMPYUTJLTKT-UHFFFAOYSA-N
FDA UNII
I60W9520VV

Vadadustat
Vadadustat is an orally bioavailable, hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor (HIF-PHI), with potential anti-anemic and anti-inflammatory activities. Upon administration, vadadustat binds to and inhibits HIF-PH, an enzyme responsible for the degradation of transcription factors in the HIF family under normal oxygen conditions. This prevents HIF breakdown and promotes HIF activity. Increased HIF activity leads to an increase in endogenous erythropoietin production, thereby enhancing erythropoiesis. It also reduces the expression of the peptide hormone hepcidin, improves iron availability, and boosts hemoglobin (Hb) levels. HIF regulates the expression of genes in response to reduced oxygen levels, including genes required for erythropoiesis and iron metabolism. In addition, HIF 1-alpha (HIF1A) may play a role in reducing inflammation during acute lung injury (ALI) through HIF-dependent control of glucose metabolism in the alveolar epithelium.
1 2D Structure

Vadadustat

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
2.1.2 InChI
InChI=1S/C14H11ClN2O4/c15-10-3-1-2-8(4-10)9-5-11(18)13(16-6-9)14(21)17-7-12(19)20/h1-6,18H,7H2,(H,17,21)(H,19,20)
2.1.3 InChI Key
JGRXMPYUTJLTKT-UHFFFAOYSA-N
2.1.4 Canonical SMILES
C1=CC(=CC(=C1)Cl)C2=CC(=C(N=C2)C(=O)NCC(=O)O)O
2.2 Other Identifiers
2.2.1 UNII
I60W9520VV
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Akb-6548

2.3.2 Depositor-Supplied Synonyms

1. 1000025-07-9

2. Akb-6548

3. Pg-1016548

4. Vadadustat [usan]

5. N-(5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl)glycine

6. B506

7. Pg1016548

8. B-506

9. Akb6548

10. (5-(3-chlorophenyl)-3-hydroxypicolinoyl)glycine

11. I60w9520vv

12. 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic Acid

13. Glycine, N-((5-(3-chlorophenyl)-3-hydroxy-2-pyridinyl)carbonyl)-

14. Glycine, N-[[5-(3-chlorophenyl)-3-hydroxy-2-pyridinyl]carbonyl]-

15. Vafseo

16. Glycine, N-[[5-(3-chlorophenyl)-3-hydroxy-2-pyridinyl]carbonyl]-;glycine, N-[[5-(3-chlorophenyl)-3-hydroxy-2-pyridinyl]carbonyl]-

17. Unii-i60w9520vv

18. Us8722895, 11: {[5-(3-chlorophenyl)-3-hydroxypyridine-2- Carbonyl]amino}-acetic Acid

19. A1z

20. Vafseo (tn)

21. Vadadustat [inn]

22. Vadadustat [jan]

23. Us8722895, 10: {[5-(3-chlorophenyl)-3-hydroxypyridine-2- Carbonyl]amino}-acetic Acid Trifluoroacetic Acid Salt

24. Vadadustat [who-dd]

25. Vadadustat (jan/usan/inn)

26. Schembl1920738

27. Chembl3646221

28. Gtpl11831

29. Bdbm107704

30. Dtxsid501179936

31. Amy27885

32. Bcp19497

33. Ex-a2573

34. 2-{[5-(3-chlorophenyl)-3-hydroxypyridin-2-yl]formamido}acetic Acid

35. Gsk128863

36. S6490

37. Zinc117532869

38. Cs-6373

39. Db12255

40. Sb19204

41. Us8598210, Table Xv, 10

42. Us8598210, Table Xv, 11

43. Ac-30928

44. As-71695

45. Db-102455

46. Hy-101277

47. Vadadustat; Pg-1016548; Akb-6548

48. J3.560.572j

49. C71001

50. D11078

51. Us8598210, 119

52. Q27280485

53. 2-(5-(3-chlorophenyl)-3-hydroxypicolinamido)acetic Acid

54. Akb-6548; B-506; Pg-1016548

55. {[5-(3-chlorophenyl)-3-hydroxy-pyridine-2-carbonyl]-amino}-acetic Acid

56. {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}-acetic Acid

2.4 Create Date
2008-01-07
3 Chemical and Physical Properties
Molecular Weight 306.70 g/mol
Molecular Formula C14H11ClN2O4
XLogP32.5
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count5
Rotatable Bond Count4
Exact Mass306.0407345 g/mol
Monoisotopic Mass306.0407345 g/mol
Topological Polar Surface Area99.5 Ų
Heavy Atom Count21
Formal Charge0
Complexity393
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Treatment of anaemia due to chronic disorders


5 Pharmacology and Biochemistry
5.1 ATC Code

B - Blood and blood forming organs

B03 - Antianemic preparations

B03X - Other antianemic preparations

B03XA - Other antianemic preparations

B03XA08 - Vadadustat


Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

STOCK RECAP #PipelineProspector

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty